Table 2.
Variable | Pre-Supplement | Post-Supplement | p-value Supplement x Time Interaction | p-value Supplement Effect |
---|---|---|---|---|
Flow-Mediated Dilation (%) | ||||
Citrulline Malate | 7.15 ± 2.44 | 9.60 ± 2.72 | < .001 | < .001a |
Nitrosigine | 8.00 ± 3.14 | 10.48 ± 2.63 | < .001a | |
Placebo | 8.01 ± 2.90 | 7.87 ± 2.83 | .76b | |
Allometric Scaled FMD % | ||||
Citrulline Malate | 7.09 ± 1.80 | 8.85 ± 1.98 | < .001 | < .001a |
Nitrosigine | 7.65 ± 2.16 | 9.47 ± 1.84 | < .001a | |
Placebo | 7.69 ± 2.17 | 7.65 ± 2.07 | .90b | |
AUC Hyperemic Shear Rate to Maximum (∫ sec−1) | ||||
Citrulline Malate | 164,109 ± 175,726 | 269,706 ± 217,793 | .30 | .01a |
Nitrosigine | 245,539 ± 190,582 | 288,877 ± 199,491 | .29b | |
Placebo | 318,179 ± 205,705 | 311,804 ± 224,332 | .92b | |
Maximum Shear Rate (sec−1) | ||||
Citrulline Malate | 771.97 ± 310.45 | 786.70 ± 253.42 | .86 | .75a |
Nitrosigine | 812.08 ± 376.58 | 790.26 ± 268.38 | .76a | |
Placebo | 918.25 ± 490.64 | 914.91 ± 367.76 | .99a |
Note. FMD flow-mediated dilation. Values are reported as mean + SD. Values with different letters represent statistically significant values